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Gestational pemphigoid, a rare autoimmune skin disease 
typically occurring during pregnancy, is caused by auto-
antibodies against collagen XVII. Clinically it is charac-
terised by severe itching followed by erythematous and 
bullous lesions of the skin. Topical or oral glucocorticoids 
usually relieve symptoms, but in more severe cases syste-
mic immunosuppressive treatments are needed. Data on 
immunosuppressive medication controlling gestational 
pemphigoid are sparse. We report 3 intractable cases of 
gestational pemphigoid treated with cyclosporine. Key 
words: pemphigoid gestationis; treatment; cyclosporine.
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Gestational pemphigoid (PG) is a rare pregnancy-associ-
ated autoimmune dermatosis with an incidence of about 
1:50,000 pregnancies (1, 2). The pathologic mechanism is 
suggestedly a local allogenic autoimmune reaction against 
collagen XVII (BP180) in the placenta, and thus a cross-
reaction with collagen XVII in the maternal cutaneous 
basement membrane (3, 4). The diagnosis is based on a 
positive direct immunofluorescence (DIF) analysis of a 
perilesional skin biopsy (5), and elevated BP180 antibody 
levels parallel disease activity (6). PG typically occurs in 
the second and 3rd trimester of pregnancy with pruritic 
urticarial papules and plaques followed by blistering (5, 
7, 8). In addition to maternal morbidity, PG is associated 
with prematurity and foetal growth restriction (8–10).
PG is usually in relative remission during the last weeks 
of pregnancy, but most patients have a flare-up at the 
time of delivery. It typically heals spontaneously within 
weeks after delivery, but may persist even for years and 
exacerbate during menstruation and hormonal contracep-
tion (5). In mild cases topical glucocorticoids combined 
with oral antihistamines are sufficiently helpful, but with 
more severe symptoms oral prednisolone is the drug-of-
choice (5). In cases unresponsive to conventional therapy, 
other immunosuppressive medications (i.e., azathioprine, 
dapsone, cyclosporine), intravenous immunoglobulin and 
plasmapheresis have been used (5, 7, 8, 11). To the best 
of our knowledge, only 2 case reports on cyclosporine 
treatment have been published (12, 13).
CASE REPORTS
Case 1. A 33-year-old healthy woman presented at gestational 
week (gw) 27+6 in her second pregnancy with pruritic skin 
symptoms that had started 2 weeks earlier on her ankles. She was 
first diagnosed to have polymorphic eruption of pregnancy and 
a potent topical glucocorticoid was initiated, but DIF analysis 
confirmed the PG diagnosis. Due to severe symptoms she was 
hospitalised at gw 28+4 with prednisolone treatment, which reli-
eved her symptoms, and the dose was later decreased. However, 
at gw 32+4 she had a drastic worsening of symptoms (Fig. 1 A, 
B) and she was re-hospitalised, and cyclosporine medication was 
combined with prednisolone. In addition, she required insulin 
treatment for her gestational diabetes. After 2 weeks her skin 
symptoms relieved and the prednisolone dose was reduced.
The mother was closely monitored in our high-risk pregnancy 
unit due to foetal growth restriction, and gestational diabetes. 
Evaluations of placental and foetal haemodynamics gave repea-
tedly normal results. At gw 36+4 she delivered spontaneously 
a growth-restricted boy (2,280 g, 6th growth percentile), who 
had an uneventful neonatal period. 
Her cyclosporine treatment was discontinued after the delivery, 
although on the first day after the delivery she had itching on her 
palms and a few new lesions appeared. Despite minor pruritic 
lesions in her extremities tapering of the prednisolone medication 
was started 6 weeks after the delivery and finally discontinued 
6 months postpartum. She had been previously diagnosed with 
endometriosis, which was under control with combined oral contra-
ceptives. This type of hormonal contraception was thought to bear 
a risk for PG recurrence. After discussion she opted for an intra-
uterine progesterone-releasing device, and has had no symptoms 
of PG or endometriosis for 6 months during lactation (Table SI1). 
Case 2. A 27-year-old healthy woman developed pruritic skin 
symptoms on her trunk and extremities at 27 gw in her first 
pregnancy. She first visited a dermatologist at 31+4 gw with 
erythema multiforme-like lesions, and was diagnosed to have 
erythema multiforme. Prednisolone combined with topical 
glucocorticoids and narrow-band UVB therapy partially re-
lieved her symptoms. After 5 weeks, these treatments were 
discontinued. However, erythema multiforme-like lesions kept 
developing, and at 38+4 gw her symptoms were aggravated. PG 
was confirmed by DIF analysis, and prednisolone and a potent 
topical glucocorticoid were initiated. 
Foetal growth restriction was detected prenatally, but umbilical 
artery velocimetry and cardiotocograms remained normal during 
the follow-up. At gw 39+3, labour was induced, and a growth-
restricted boy (2,595 g, 4th growth percentile) was delivered. 
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Maternal skin symptoms worsened immediately after the 
delivery and oral prednisolone dose was increased. As blistering 
and intense itching continued, cyclosporine was combined with 
her medication a few days after the delivery. Prednisolone was 
then slowly tapered. While pruritus and blistering continued and 
the BP180 levels remained above 150 IU/ml, the cyclosporine 
dose was increased. After 3 weeks on the higher cyclosporine 
dose her skin symptoms relieved, and due to mildly elevated 
creatinine levels (96 µmol/l) the dose was decreased and 
prednisolone was continued. Due to provoking symptoms her 
prednisolone medication could not be tapered, and 8 months 
after the delivery methotrexate was added to her medication, 
simultaneously with start of combined oral contraceptives 
(ethinyl estradiol with drospirenone). Two months after the 
initiation of this combination no new blisters had appeared, 
but she still had mild erythema on her chest and scalp. She was 
symptom-free one year after the delivery, and cyclosporine was 
discontinued, prednisolone dose tapered and she continued with 
methotrexate. A relapse with pruritic papules occurred rapidly, 
and cyclosporine and prednisolone were re-initiated. Two weeks 
after the relapse cyclosporine was successfully discontinued 
and she continued on prednisolone and methotrexate. Tapering 
of the prednisolone dose 15 months after the delivery led to 
an immediate activation of her symptoms. Methotrexate was 
increased to 15 mg/week for 3 months, and prednisolone was 
finally slowly discontinued 19 months postpartum with no 
signs of cortisol deficiency. Her methotrexate medication was 
discontinued successfully 22 months postpartum, and 2 years 
after the delivery, she is finally symptom-free (Table SI1)
Case 3. A 32-year-old healthy woman presented at 26+6 in her 
4th pregnancy with a pruritic eruption spreading over the body 
and extremities. PG was confirmed at gw 27+2 by DIF analysis. 
Oral prednisolone combined with hydroxyzine and a topical 
glucocorticoids was started. After a week the prednisolone dose 
was increased since blistering continued, and at gw 29+5 she was 
hospitalised with cyclosporine medication. Disease control was 
achieved and after 5 weeks without flaring (34+3), cyclosporine 
and prednisolone were tapered, but due to a non-blistering eruption 
the prednisolone dose was slightly increased to control the disease.
Antenatal foetal monitoring tests were normal during the obstet-
ric follow-up. At gw 35+4 she was hospitalised due to decreased 
foetal movements, proceeded to spontaneous preterm delivery, and 
delivered a healthy girl (2,870g, 63th growth percentile). The pa-
tient decided to discontinue the cyclosporine therapy immediately 
after the delivery and remained on prednisolone monotherapy. A 
flare-up blistering occurred rapidly, but subsided within 6 weeks, 
and prednisolone was tapered during the following 2 months. Two 
months after the delivery BP180 antibodies were still elevated, 
but she has had no flare-ups for 4 years and uses non-hormonal 
contraception. Her BP180 antibody levels have not been evaluated 
later (Table SI1). This pregnancy is included in our earlier study 
(10), without giving any details about her cyclosporine therapy. 
DISCUSSION
Most PG patients can be successfully treated with topical 
and oral glucocorticoids, which are considered relatively 
safe during pregnancy (14, 15). Data on severe PG cases 
with immunosuppressive medication are sparse, and the 
benefit to the mother needs to be weighed against pos-
sible risks to the foetus and the newborn. Cyclosporine 
down-regulates T-cell function, and it has been used 
during pregnancy in organ transplant patients and in 
various autoimmune diseases with no association with 
increased risk of congenital malformations (16). As a 
lipophilic agent, cyclosporine diffuses across the pla-
centa and enters the foetal circulation and tissues (16), 
and can increase foetal exposure to other drugs (17). In 
previous reports maternal and foetal risks have mostly 
been associated with maternal comorbidities and multi-
ple immunosuppressive drugs (16). 
Maternal BP180 antibody levels were highly elevated 
already at the time of PG diagnosis in all cases (Table SI1). 
Cyclosporine treatment was started according to clinical 
symptoms, but BP180 antibody levels were above 110 IU/
ml in all cases at the beginning of the treatment. In our 
previous series, BP180 levels varied between 27–50 IU/
ml in patients who were successfully treated with systemic 
glucocorticoids (10). In the present study, maternal BP180 
antibody levels correlated well with disease activity, as de-
scribed earlier (6), and decreased before cyclosporine was 
weaned off (Table SI1), strengthening the suggestion that 
BP180 antibody levels can guide treatment decisions (18). 
Previously, cyclosporine has been used postnatally 
in combination with prednisolone after intravenous im-
munoglobulin treatment in one severe persistent PG case 
lasting for 1.5 years (13) and antenatally in one case, 
in which 100 mg/day cyclosporine was combined with 
prednisolone 25 mg/day (12). Our patients were treated 
with higher cyclosporine (100–400 mg/day; 1.5–2.7 mg/
kg/day) and prednisolone (40–60 mg/day; 0.55–0.67 mg/
kg/day) doses. These doses are in line with previously 
reported medications used in severe psoriasis during 
pregnancy (19, 20). Cyclosporine was well tolerated by 
the present patients. In case 2 the dose was reduced due 
to mildly elevated maternal serum creatinine level, but 
none of our patients developed hypertensive disorders or 
Fig. 1. Clinical presentation of  case 1. A: Widespread urticarial and partially 
blistering eruption. B: Erythematous non-blistering eruption on soles.
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systemic infections. However, close maternal and foetal 
follow-up is warranted due to risks of infection (1–71%), 
premature delivery (21%), foetal growth restriction (21%) 
and maternal kidney changes becoming irreversible (16). 
Two of our patients with antenatal cyclosporine therapy 
proceeded to spontaneous preterm delivery at 35–36 
weeks and 2 neonates were growth-restricted (one with 
antenatal cyclosporine therapy) with no haemodynamic 
signs of foetal blood flow redistribution or maternal hy-
pertensive disorders. Prematurity and low birth weight are 
associated with both PG and cyclosporine medication (9, 
10, 16). Among 19 psoriatic patients, both foetal growth 
restriction and premature delivery occurred in 21% of the 
pregnancies treated with cyclosporine (16). Systemic glu-
cocorticoid therapy can also increase the risk of maternal 
hypertension and low birth weight (21). It is difficult to 
estimate whether the adverse perinatal outcomes in this 
study are solely due to severe PG or whether the medica-
tion played a role. However, we underline that these pa-
tients should be closely monitored by their dermatologists 
as well as their obstetricians. 
Cyclosporine is excreted to breast milk and the Ame-
rican Association of Pediatrics advises against breast-
feeding during the medication (22). However, among 15 
cumulative breastfed cases, cyclosporine was detected 
in the neonatal circulation only in one case and normal 
growth and development has been reported in all cases 
(23–27). Due to the relatively small amount of drug 
transferred and the lack of reported adverse effects, we 
let the mothers breastfeed their babies. In case 2, the 
cyclosporine levels in the infant’s circulation were eva-
luated, and no cyclosporine was detected. The infants in 
the present study developed normally during the first 6 
months–2 years, which is in line with previous follow-up 
reports of the offspring up to 15 years of age (28).  
In conclusion, cyclosporine treatment can be conside-
red antenatally when treating severe and persistent PG 
unresponsive to topical and systemic glucocorticoids. 
In addition to dermatologic follow-up, close obstetric 
follow-up is warranted due to the risks of premature 
delivery and fetal growth restriction.
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